Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

  • Posts
    • AACR18
    • AACR17
    • AACR16
    • AACR15
    • AACR14
    • AACR IO
    • AAI ASGCT 2015 New Orleans
    • ASCO-SITC
    • ASCO18
    • ASCO17
    • ASCO16
    • ASCO15
    • ASCO14
    • ASCO GU18
    • ASCO GI18
    • ASCO GI 2017
    • ASCO GU CI 2016
    • ASCO GI GU 2015
    • ASCO GI GU 2014
    • ASH18
    • ASH17
    • ASH16
    • ASH15
    • ASH14
    • ASH13
    • AUA 2015
    • AUA 2014
    • BMT Tandem
    • CIML40
    • EACR
    • EAU 2015 Congress
    • EBMT15
    • ESMO IO
    • ESMO18
    • ESMO17
    • ESMO16
    • ECC 2015
    • ESMO14
    • ECC 2013
    • European Breast Cancer Conference
    • European Lung Cancer Conf
    • JPM18
    • JPM17
    • JPM16
    • JPM15
    • JPM14
    • Miami Breast Cancer Conference
    • Targets17
    • Mol Targets 2016
    • Molecular Targets
    • SABCS17
    • SABCS16
    • SABCS15
    • SABCS14
    • SABCS13
    • SGO
    • SITC 2017
    • SITC 2016
    • SITC 2015
    • SITC 2014
    • WCLC
  • About
  • Contact
  • Interviews
  • SITC 2018
  • Immuno-Oncology
  • Premium Content
  • Pricing
  • Login

  • What can we learn from early IO trials?

    Read more

  • Learning from failure with IO combos

    Read more

  • Pinning down potential new opportunities for IL–8 and 4–1BB

    Read more

  • An analysis of Nektar’s latest PIVOT data and pipeline update

    Read more

  • How the microbiota impact response to cancer immunotherapy

    Read more

  • New developments in immune escape

    Read more

  • Creating order from the ASH18 data dump

    Read more
E

What can we learn from early IO trials?

There are a number of important lessons we can learn from early phase 1 trials. Here are some of them.

View post
E

Learning from failure with IO combos

AstraZeneca miss on OS in the phase 3 MYSTIC trial – what next?…

View post
E

Pinning down potential new opportunities for IL–8 and 4–1BB

What is old is new again - a look at some forgotten oncology targets that are coming back in fashion

View post

Terms of Use & Privacy Policy
Copyright © 2010-18 Biotech Strategy Blog

Sign Up for New Post Alerts
error: Content is protected !!